{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:57Z","timestamp":1740144237873,"version":"3.37.3"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"crossref","award":["SALUD-14-01-234292"],"award-info":[{"award-number":["SALUD-14-01-234292"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007686","name":"Instituto Nacional de Perinatolog\u00eda","doi-asserted-by":"crossref","award":["(478) 212250-3120771"],"award-info":[{"award-number":["(478) 212250-3120771"]}],"id":[{"id":"10.13039\/501100007686","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Simultaneous therapeutic drug monitoring (TDM) of combination antiretroviral therapy (cART) is critical during pregnancy in order to improve clinical follow-up, monitor viral load, and patient adherence to treatment.<\/jats:p>\n            <jats:p>A modified simple and fast ultra-high performance liquid chromatography coupled with tandem mass spectrometry and electrospray ionization (UPLC-ESI-MS\/MS) method was developed and validated according to national and international guidelines for the simultaneous determination of lamivudine (LMV), zidovudine (ZDV), lopinavir (LPV), and ritonavir (RTV) concentrations in 100-\u03bcL plasma sample of Human Immunodeficiency Virus (HIV)-positive pregnant women. Protein precipitation using 0.1% formic acid in cold acetonitrile was used for sample preparation. The chromatographic separation was achieved with a run-time of 3.0\u200aminutes and 3-\u03bcL injection on an ethylene bridged hybrid C18 column (2.1\u200a\u03bcm \u00d7 50\u200amm, 1.7\u200a\u03bcm), under gradient conditions using acetonitrile and formic acid (0.1%).<\/jats:p>\n            <jats:p>The chromatographic method was used to analyze 10 plasma samples from 8 HIV pregnant women as a clinical patient routinely follow-up by applying TDM criteria.<\/jats:p>\n            <jats:p>The protonated precursor\/product ion transitions for LMV (230.18\/112.08), ZDV (268.22\/127.10), LPV (629.55\/447.35), and RTV (721.50\/296.20) were recorded in multiple-reaction-monitoring (MRM) mode. The calibration curve was linear in the range of 50\u20133,000, 75\u20134,500, 250\u201315,000, and 25\u20131,500-ng\/mL for LMV, ZDV, LPV, and RTV, respectively. The range of accuracy was 97.2% to 100.1% and precision 3.4% to 12.7%. The method showed specificity and matrix effect values of\u200a&lt;\u200a15%. Minimum absolute recovery percentages (%CV) were 90.5 (5.4), 90.8 (5.0), 95.4 (3.5), and 93.7 (6.9), for LMV, ZDV, LPV, and RTV, respectively. Drug concentrations in patient samples had high inter-individual variability with %CV of 91.98%, 77.54%, 53.80%, and 92.16% for ZDV, LMV, LPV, and RTV, respectively. Two of the 8 patients showed no adherence due to the absence of Protease Inhibitors (PIs) levels in plasma.<\/jats:p>\n            <jats:p>This technique demonstrated to be effective in therapeutic drug monitoring and is intended to be used in population pharmacokinetics specifically for HIV-positive pregnant women.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020487","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:22:06Z","timestamp":1590693726000},"page":"e20487","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-0912","authenticated-orcid":false,"given":"Jessica","family":"Hern\u00e1ndez-Pineda","sequence":"first","affiliation":[{"name":"Departamento de Infectolog\u00eda e Inmunolog\u00eda. Instituto Nacional de Perinatolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi Helene","family":"Jung-Cook","sequence":"additional","affiliation":[{"name":"Facultad de Qu\u00edmica. Universidad Nacional Aut\u00f3noma de M\u00e9xico. Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah Lucky","family":"Katende-Kyenda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pharmacology, Walter Sisulu University, School of Medicine, Faculty of Health Sciences, Mthatha, Eastern Cape, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Galindo-Sevilla","sequence":"additional","affiliation":[{"name":"Departamento de Infectolog\u00eda e Inmunolog\u00eda. Instituto Nacional de Perinatolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Dom\u00ednguez-Castro","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda y Desarrollo Celular. Instituto Nacional de Perinatolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Romo-Ya\u00f1\u00e9z","sequence":"additional","affiliation":[{"name":"Coordinaci\u00f3n de Endocrinolog\u00eda Ginecol\u00f3gica y Perinatal. Instituto Nacional de Perinatolog\u00eda, Mexico City, Mexico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Ram\u00edrez-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Departamento de Infectolog\u00eda e Inmunolog\u00eda. Instituto Nacional de Perinatolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Irles","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda y Desarrollo Celular. Instituto Nacional de Perinatolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Figueroa-Dami\u00e1n","sequence":"additional","affiliation":[{"name":"Departamento de Infectolog\u00eda e Inmunolog\u00eda. Instituto Nacional de Perinatolog\u00eda"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"R1-20240308","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eimc.2018.02.010","article-title":"Executive summary of the GeSIDA\/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)","volume":"37","year":"2019","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R2-20240308","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eimc.2016.02.028","article-title":"Executive summary of the GESIDA\/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016)","volume":"34","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"R5-20240308","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20240308","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.2008.03220.x","article-title":"Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women","volume":"66","author":"Roustit","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20240308","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jac\/dkp123","article-title":"Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment","author":"Bouillon-Pichault","year":"2009","journal-title":"J Antimicrob Chemother V 63"},{"key":"R8-20240308","first-page":"286","article-title":"Adherencia a los f\u00e1rmacos antirretrovirales medida por la concentraci\u00f3n de f\u00e1rmacos y el recuento de comprimidos. Variables relacionadas con una mala adherencia","volume":"119","author":"Riera","year":"2002","journal-title":"Med Cl\u00edn"},{"key":"R9-20240308","first-page":"130","article-title":"Estudios de adherencia a los f\u00e1rmacos antirretrovirales. Una revisi\u00f3n sistem\u00e1tica","volume":"119","author":"Puigvent\u00f3s","year":"2002","journal-title":"Med Cl\u00edn"},{"key":"R10-20240308","first-page":"500","article-title":"Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice","volume":"62","author":"Higgins","year":"2009","journal-title":"Can J Hosp Pharm"},{"key":"R11-20240308","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2016.03.019","article-title":"The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine","author":"Decosterd","year":"2016","journal-title":"TrAC Trends Anal Chem"},{"key":"R13-20240308","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4155\/bio.13.298","article-title":"New US FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR","volume":"6","author":"Zimmer","year":"2014","journal-title":"Bioanalysis"},{"key":"R14-20240308","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"R15-20240308","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.ftd.0000152680.36517.5d","article-title":"Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography","volume":"27","author":"Poirier","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R16-20240308","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jpha.2016.05.008","article-title":"Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients","volume":"6","author":"Charbe","year":"2016","journal-title":"J Pharm Anal"},{"key":"R17-20240308","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/hiv.12164","article-title":"Therapeutic drug monitoring of atazanavir\/ritonavir in pregnancy","volume":"15","author":"Else","year":"2014","journal-title":"HIV Med"},{"key":"R18-20240308","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2011.09.041","article-title":"Therapeutic drug monitoring and LC-MS\/MS","volume":"883-884","author":"Adaway","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R19-20240308","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1590\/S0103-50532011000100018","article-title":"Ultra-performance liquid chromatographic method for simultaneous quantification of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors in human plasma","volume":"22","author":"Antunes","year":"2011","journal-title":"J Braz Chem Soc"},{"key":"R20-20240308","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4155\/bio.12.319","article-title":"Antiretroviral bioanalysis methods of tissues and body biofluids","volume":"5","author":"DiFrancesco","year":"2013","journal-title":"Bioanalysis"},{"key":"R21-20240308","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R22-20240308","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijpharm.2005.03.002","article-title":"Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies","volume":"297","author":"Kano","year":"2005","journal-title":"Int J Pharm"},{"key":"R23-20240308","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.apsb.2012.07.003","article-title":"Simultaneous quantitation of lamivudine, zidovudine and nevirapine in human plasma by liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study","volume":"2","author":"Matta","year":"2012","journal-title":"Acta Pharm Sin B"},{"key":"R24-20240308","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/iub.1025","article-title":"Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS\/MS","volume":"64","author":"Notaril","year":"2012","journal-title":"IUBMB life"},{"key":"R25-20240308","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jpba.2009.02.010","article-title":"Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS\/MS for bioequivalence study in Indian subjects","volume":"49","author":"Yadav","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"R26-20240308","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.aca.2009.08.010","article-title":"Rapid, simultaneous determination of lopinavir and ritonavir in human plasma by stacking protein precipitations and salting-out assisted liquid\/liquid extraction, and ultrafast LC-MS\/MS","volume":"651","author":"Myasein","year":"2009","journal-title":"Anal Chim Acta"},{"key":"R27-20240308","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/rcm.3138","article-title":"Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma","volume":"21","author":"Gehrig","year":"2007","journal-title":"Rapid Commun Mass Spectr"},{"key":"R28-20240308","first-page":"Cd007268","article-title":"Therapeutic drug monitoring of antiretrovirals for people with HIV","author":"Kredo","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R29-20240308","doi-asserted-by":"crossref","first-page":"e4170","DOI":"10.1002\/bmc.4170","article-title":"Chromatographic methods in HIV medicine: application to therapeutic drug monitoring","volume":"32","author":"Archibald","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"R30-20240308","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11904-017-0353-0","article-title":"Long-acting antiretrovirals: where are we now?","volume":"14","author":"Nyaku","year":"2017","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R31-20240308","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrd1151","article-title":"Toxicity of antiretroviral therapy and implications for drug","volume":"2","author":"Carr","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"R32-20240308","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/00365548.2011.642306","article-title":"Lopinavir\/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy","volume":"44","author":"Calza","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"R33-20240308","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/QAD.0b013e328031f42e","article-title":"Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine","volume":"21","author":"Manavi","year":"2007","journal-title":"Aids"},{"key":"R34-20240308","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/phar.2333","article-title":"A review of clinical pharmacokinetic and pharmacodynamic profiles of select antiretrovirals: focus on differences among chinese patients","volume":"39","author":"Du","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R35-20240308","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nrd3002","article-title":"New approaches to drug safety: a pharmacovigilance tool kit","volume":"8","author":"Wise","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"R36-20240308","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2105\/AJPH.2005.068668","article-title":"Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research","volume":"95","author":"Burchard","year":"2006","journal-title":"Am J Public Health"},{"key":"R37-20240308","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1310\/hct1104-230","article-title":"Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients","volume":"11","author":"Ye","year":"2010","journal-title":"HIV Clinical Trials"},{"key":"R38-20240308","first-page":"1931","article-title":"Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients","volume":"125","author":"LIU","year":"2012","journal-title":"Chin Med J"},{"key":"R39-20240308","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/0091270010376971","article-title":"Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers","volume":"51","author":"Huang","year":"2011","journal-title":"J Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:17:13Z","timestamp":1709929033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020487"}},"subtitle":["Drug monitoring application to improve patient safety"],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":36,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020487","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,5,29]]}}}